Clinical Trial Update: Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating zanubrutinib with tislelizumab for relapsed/refractory primary mediastinal large B-cell lymphoma and EBV-positive DLBCL.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebv-positive Dlbcl
• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• Tislelizumab (tislelizumab)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Ruijin Hospital | Conditions: Primary Mediastinal Large B Cell Lymphoma, EBV-Positive DLBCL, Nos | Phase 2 | Status: UNKNOWN